AGIO
NASDAQ HealthcareAgios Pharmaceuticals, Inc. - Common Stock
Biotechnology
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
�� 市场数据
| 价格 | $35.14 |
|---|---|
| 成交量 | 654,199 |
| 市值 | 2.06B |
| 贝塔系数 | 0.790 |
| RSI（14日） | 76.2 超买 |
| 200日均线 | $33.79 |
| 50日均线 | $29.93 |
| 52周最高 | $46.00 |
| 52周最低 | $22.24 |
| Forward P/E | -7.18 |
| Price / Book | 1.72 |
🎯 投资策略评分
AGIO 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🎈 Over-Hyped (61/100) — 此策略 超买股票（潜在做空标的）.
评分最低的策略： 🚀 Moon Shot (32/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 AGIO in your text
粘贴任何文章、记录或帖子 — 工具将提取 AGIO 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.